Canadian Cancer Trials Group Bulletins

General


Recent Publications

MAP.2 (A Randomized Study of the Effect of Exemestane [Aromasin] versus Placebo on Breast Density in Postmenopausal Women at Increased Risk for Development of Breast Cancer)

Cigler T, Richardson H, Yaffe MJ, Fabian CJ, Johnston D, Ingle JN, Nassif E, Brunner RL, Wood ME, Pater JL, Hu H, Qi S, Tu D, Goss PE. A randomized, placebo-controlled trial (Canadian Cancer Trials Group MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women (ONLINE). Breast Cancer Res Treat 2011.

http://springerlink.metapress.com/content/e78017077w5251t5/


MA.32 (A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer)

Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126: 215-20, 2011.

http://www.springerlink.com/content/f240834126253437/